Annual report pursuant to Section 13 and 15(d)

Revenues from Contracts and Significant Customers - Additional Information (Detail)

v3.19.1
Revenues from Contracts and Significant Customers - Additional Information (Detail) - USD ($)
 1 Months Ended 12 Months Ended
Oct. 29, 2018
Feb. 28, 2015
Dec. 31, 2018
Dec. 31, 2017
Return Reserve     $ 2,400,000 $ 1,200,000
Revenue from Contract with Customer, Including Assessed Tax     23,376,000 15,520,000
Revenue Recognition Milestone Method Payments Due $ 2,000,000      
Allowance for Doubtful Accounts Receivable     3,100,000 1,300,000
Sale Millstone [Member]        
Revenue Recognition Milestone Method Payments Due   $ 26,200,000    
Checkpoint Therapeutics, Inc [Member] | First Commercial Sale Milestone [Member]        
Revenue Recognition Milestone Method Payments Due     21,500,000  
Checkpoint Therapeutics, Inc [Member] | Additional Sales Milestone [Member]        
Revenue Recognition Milestone Method Payments Due     60,000,000  
Checkpoint Therapeutics, Inc [Member] | Commercial Sales In Specified Territories [Member]        
Revenue Recognition Milestone Method Payments Due     14,500,000  
Checkpoint Therapeutics, Inc [Member] | Successful Achievement Of One Preclinical Milestone [Member]        
Revenue Recognition Milestone Method Payments Due     25,500,000  
Checkpoint Therapeutics, Inc [Member] | Clinical Development And Regulatory Milestones [Member]        
Revenue Recognition Milestone Method Payments Due     7,000,000  
Customer One [Member]        
Revenue from Contract with Customer, Including Assessed Tax     48,500,000 26,000,000
Accounts Receivable, Net       20,800,000
Customer Two [Member]        
Revenue from Contract with Customer, Including Assessed Tax     10,600,000 18,500,000
Customer Three [Member]        
Revenue from Contract with Customer, Including Assessed Tax       13,100,000
Accounts Receivable, Net       16,500,000
Checkpoint Collaboration Agreement With Tgtx Related To Jubliant License [Member]        
Revenue Recognition Milestone Method Payments Due     400,000 1,000,000
Payment Of Upfront Licensing Fee     $ 1,000,000  
Research And Development Cost Shared Percentage     50.00%  
Checkpoint Collaboration Agreement With Tgtx Related To Jubliant License [Member] | Clinical Development And Regulatory Milestones [Member]        
Revenue Recognition Milestone Method Payments Due     $ 87,200,000  
Checkpoint Collaboration Agreement With Tgtx Related To Jubliant License [Member] | Five Regulatory Approvals And First Commercial Sales [Member]        
Revenue Recognition Milestone Method Payments Due     61,700,000  
Checkpoint Collaboration Agreement With Tgtx Related To Jubliant License [Member] | Sale Millstone [Member]        
Revenue Recognition Milestone Method Payments Due     89,000,000  
Checkpoint Collaboration Agreement With Tgtx Related To Jubliant License [Member] | Checkpoint Therapeutics, Inc [Member]        
Revenue Recognition Milestone Method Payments Due     500,000  
Checkpoint Collaboration Agreement with TGTX NeuPharma, Inc. and TGTX [Member]        
Revenue Recognition Milestone Method Payments Due     35,000 600,000
Checkpoint Collaboration Agreement With TGTX Related To DanaFarber License [Member]        
Revenue Recognition Milestone Method Payments Due     3,000,000 $ 100,000
License and Service [Member]        
Revenue from Contract with Customer, Including Assessed Tax     $ 3,600,000